PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Clinical trials for PULMONARY ALVEOLAR PROTEINOSIS (PAP) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ALVEOLAR PROTEINOSIS (PAP) trials appear
Sign up with your email to follow new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial targets Body's Self-Attacking immune cells
Disease control CompletedThis study tested whether a drug called rituximab could safely treat rare diseases where the immune system mistakenly attacks the body's own proteins. Seven adults with these conditions, who were not helped by standard treatments, received rituximab infusions over six months. The…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists probe genetic clue to rare childhood lung disease
Knowledge-focused CompletedThis study aimed to understand how a specific genetic mutation (in the MARS gene) causes a rare lung disease called pulmonary alveolar proteinosis (PAP) in children. Researchers compared immune cells from 20 children with and without this mutation to see if their cells could prop…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC